Friday, July 10, 2026

biotech · SARS-CoV-2 Infection · Breast Cancer

Henlius USA

Shanghai Henlius Biotech is a biotech organization headquartered in CN. Primary therapeutic focus areas include SARS-CoV-2 Infection, Breast Cancer, HLX07, nsqNSCLC, High EGFR Expression. NovaPharmaNews links 3 clinical

Milpitas, USA HQ
2010 Founded
45 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Milpitas, USA
Founded
2010
Employees
45
Programs
3
Drugs
4
Patents
0
Clinical program

Azvudine

Phase 3 · small molecule · SARS-CoV-2 Infection

Azvudine for SARS-CoV-2 Infection is a Phase 3 program (small_molecule) at Shanghai Henlius Biotech with 1 ClinicalTrials.gov record(s).

← All Shanghai Henlius Biotech projects Phase 3 small molecule active

Internal code FNC-Covid304

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Shanghai Henlius Biotech
Phase
Phase 3
Modality
small_molecule
Indication
SARS-CoV-2 Infection
Status
active
Trials
1

Clinical trials